13G Filing: Partner Fund Management and Coherus Biosciences Inc. (CHRS)
...... (read more)
Coherus Biosciences Inc. (CHRS)
Get Email Alerts Insider Trading: Purchases See All
| Insider | Price | Amount | Relationship | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $13.50 | 425,926 | Director | 2,557,759 | 2014-11-12 | Filing | |
| $13.50 | 164,963 | Other | 3,042,019 | 2014-11-12 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Relationship | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $15.00 | 1,760 | Officer | 37,043 | 2018-06-18 | Filing | |
| $16.26 | 20,984 | Officer, Director | 1,316,582 | 2018-05-16 | Filing | |
| $15.02 | 17,535 | Officer | 49,651 | 2017-08-08 | Filing | |
| $15.00 | 600 | Officer | 67,186 | 2017-07-05 | Filing | |
| $20.98 | 1,732 | Officer | 67,786 | 2017-06-01 | Filing |
News See All
Coherus Biosciences Inc (CHRS) Could Be A Discount Entry On The Pullback
Coherus Biosciences Inc (NASDAQ:CHRS) just announced that it has kicked off a public offering that will se it unload $125 million worth of its common stock, alongside an additional grant to the underwriters...... (read more)
Hedge Funds Are Betting On Coherus Biosciences Inc (CHRS)
Reputable billionaire investors such as Nelson Peltz and David Tepper generate exorbitant profits for their wealthy accredited investors (a minimum of $1 million in investable assets would be required...... (read more)
AbbVie Inc (ABBV) Wins Patent Battle Against Coherus Biosciences Inc (CHRS)
The US Patent and Trademark Office (USPTO) Patent Trial and Appeal Board (PTAB) has decided not to embark on the review of the 166 formulation patent of AbbVie Inc (NYSE:ABBV) as requested by Coherus...... (read more)
AbbVie Inc (ABBV) Stock: Skyrocketing On IP Chatter | Coherus Biosciences Inc (CHRS) Stock Tanking
AbbVie Inc (NYSE:ABBV) and Coherus Biosciences Inc (NASDAQ:CHRS) were both off to a relatively normal start in the market today. While both were trading in the green, they weren't gaining by much. That...... (read more)
Coherus Biosciences Inc (CHRS) Has Set Its Sights On Amgen, Inc. (AMGN)
Coherus Biosciences Inc (NASDAQ:CHRS) submitted a biologics licensing application (BLA) for its lead biosimilar development candidate earlier this month, and is drawing a lot of speculative attention...... (read more)
Yelp Inc (YELP) Swung To Surprising Profit; A Look at Four Other Earnings Reports
No major moves in the US stock market this Wednesday morning, as investors digest retail earnings reports and are keeping an eye on oil prices. Analysts are expecting the market to be calm over the next...... (read more)
Coherus Biosciences Inc (CHRS) Is Looking To Compete With Amgen, Inc. (AMGN)’s Cancer Blockbuster
The biosimilar space is relatively young. Only across the last handful of of years has the FDA put firm regulatory processes in place for the approval pathway, and only a couple of biosimilar drugs –...... (read more)
Why Coherus Biosciences, Hortonworks and 3 Other Stocks Are Posting Big Gains Today
The markets are off to a rocking start this week on the back of growing optimism after a strong jobs report on Friday, and waning uncertainty around the global economy after Japanese Prime Minister Shinzo...... (read more)
13G Filing: Healthcare Royalty Partners III, L.p. and Coherus Biosciences, Inc. (CHRS)
The remainder of this cover page shall be filled out for a reporting persons initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information...... (read more)
Billionaire Hedge Funds
